- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
- Industry news
- Development
News of the day
Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
NICE, France, May 14, 2008 -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) reported for the first time at the European Stroke Conference detailed analyses supporting the dosing regimen in NTI's two ongoing Phase 3 studies of Viprinex(TM) (ancrod) for ischemic stroke. The company also provided information as to why it believes these studies are more likely to be successful in treating ischemic stroke than previous Phase 3 clinical trials conducted by others using the same snake... moreMylan Launches Paroxetine Hydrochloride Extended-Release Tablets
PITTSBURGH, May 14, 2008 -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has launched Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GlaxoSmithKline's (GSK) Paxil CR®. As the first company to successfully file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the 12.5 mg and 25 mg tablets, Mylan has earned 180 days of marketing exclusivity for these two strengths. Reflecting a supply and... moreAlseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
HOPKINTON, Mass., May 12, 2008-- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation. The data for these first 37 patients indicate that at 6 and 12 months after... moreIndustry news search
Most Viewed News
- POSITIVE RESULTS FROM PHASE I CLINICAL TRIAL OF SMT D002 FOR THE TREATMENT OF SEBORRHOEA, A PRIMARY CAUSE OF ACNE
- Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer
- Roche fully acquires privately-owned biotech company Piramed
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
- RSS Feed...
Recent news
To keep up to date with news from this category use our
NOVELOS THERAPEUTICS ANNOUNCES POSITIVE RESULTS IN ONGOING PHASE 2 NEOADJUVANT BREAST CANCER TRIAL AT MUSC HOLLINGS CANCER CENTER
NEWTON, Mass., May 12, 2008 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced positive interim results in...
Starpharma Reports Positive VivaGel® Clinical Study Results
Melbourne, Australia, 12 May 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced positive results of a clinical trial that achieved all its objectives demonstrating that 3% SPL7013 Gel (VivaGel®)...
Extended accrual time and decreased sample size for Marshall Edwards' OVATURE trial
Sydney, Australia; London, UK and New Canaan, Conn. - 9 May 2008 - The accrual time for the OVArian TUmor REsponse (OVATURE) clinical study, a Phase III study of the investigational chemosensitizing drug, phenoxodiol,...
VIRTUALSCOPICS ANNOUNCES RESULTS OF ANNUAL STOCKHOLDERS' MEETING
ROCHESTER, NY - May 9, 2008 - VirtualScopics, Inc. (NasdaqCM: VSCP), a leading provider of advanced medical imaging for clinical trials, today announced the results of its annual stockholders' meeting held on May 8,...
Orion has decided not to continue the development of a new COMT inhibitor candidate
May 09, 2008--Orion Corporation has decided not to continue the development of their new COMT inhibitor, which has now progressed to the end of clinical Phase I. Based on the overall results received from the studies...
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Cyclophosphamide Trial
CALGARY, AB, --- May 9, 2008 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has begun patient enrolment in a clinical trial using intravenous administration of REOLYSIN® in...
St. Jude Medical to Launch New Brand Identity
ST. PAUL, Minn., May 09, 2008 -- St. Jude Medical, Inc. (NYSE: STJ) today announced it will unveil its new corporate identity to physician customers at the 88th Annual Meeting of the American Association of Thoracic...
Philips launches new release of its top-rated Xcelera cardiology information management solution
Andover, Mass.-May 09, 2008 Royal Philips Electronics (NYSE: PHG; AEX: PHI) today announced volume shipments of a new version of its Xcelera multimodality cardiology image management, analysis and reporting solution....
Artes Medical Reports Strong Consumer Interest, Rapid Patient Enrollment and Positive Feedback in Largest U.S. Dermal Filler Clinical Study
SAN DIEGO--May 9, 2008--Artes Medical, Inc. (Nasdaq:ARTE) today reported strong consumer interest, rapid patient enrollment and positive feedback in what it believes is the largest US-based post-marketing safety and...
New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective For Acute Pain From Common Foot Surgery
Tampa, FL (May 9, 2008) - Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot surgeries. The investigational pain medication tapentadol provided...
New Study Suggests Tapentadol IR For Acute Pain is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Tampa, FL (May 9, 2008) - Many strong acting pain medications have bothersome side effects. These can include nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead...
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
Tampa, FL (May 9, 2008) - Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The...
Almac Diagnostics in new deal to provide unique process to extract genetic information from Clinical Trial samples
May 08, 2008-The Almac Group today announced a deal with Biogen Idec Inc (NASDAQ: BIB) a global biotechnology company based in Cambridge, Mass., to use Almac Diagnostics' expertise in extracting genetic information from...
Collegium Pharmaceutical Inc. Presents Clinical Data for DETERx(TM) Abuse-Deterrent Sustained Release Technology at American Pain Society Meeting
CUMBERLAND, RI-- May 8, 2008 -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the presentation of a scientific poster summarizing the results of a pharmacokinetic study for its...
Savient Reports Favorable Interim Data from Puricase(R) (pegloticase) Open Label Extension Study
EAST BRUNSWICK, N.J., May 07, 2008 -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), today announced positive interim data from the ongoing pegloticase open label extension (OLE) to the Phase 3 pivotal trials in patients...
Discovery Labs Presents Surfaxin® Data at Pediatric Academic Societies Annual Meeting
Warrington, PA - May 7, 2008 -- Discovery Laboratories, Inc. (Nasdaq: DSCO), announced that SURFAXIN® pre-clinical and clinical data were presented at the Pediatric Academic Societies Annual Meeting. The Pediatric...
Biosimilar G-CSF: Cooperation on Three Continents.
Toronto, ON (May 7, 2008) -- A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals...
Pevion Biotech signs Cooperation Agreement with ISS
Bern, May 7th 2008 - The Istituto Superiore di Sanità (ISS) has signed an agreement with the Swiss biotechnology company Pevion Biotech Ltd for production and further clinical development of a vaccine against vaginal...
Nothing depressing about launch of Cipla's Lexamil
May 07, 2008 -- With more and more psychiatrists favouring escitalopram as a first-line antidepressant, local pharmaceutical company Cipla Medpro (Pty) Ltd has released South Africa's first generic escitalopram, Lexamil.
Sigma-Aldrich to Provide Full Functional Validation Data for Its MISSION(R) shRNA Collection
ST. LOUIS, May 7, 2008-- Sigma-Aldrich(TM) (Nasdaq: SIAL) and the second phase of The RNAi Consortium (TRC2) have commenced functional validation of the Consortium's collection of approximately 160,000 previously-cloned...
STANFORD UNIVERSITY TO STUDY GENOMICS-BASED DIAGNOSTIC TEST FOR UNCERTAIN TUMORS
Sunnyvale, Calif., May 6, 2008 --- Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, announced today that Stanford University School of Medicine has initiated an investigational study of...
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., May 6, 2008 -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical...
Prana's Drug Library has Discovered Novel Drug Candidates for Use in Parkinson's Disease
MELBOURNE, Australia - May 6, 2008: Prana Biotechnology Limited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today...
Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
Basel, May 6, 2008 - New Phase III data for Menveo® (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to...
Aethlon Hemopurifier(R) Effective in Capturing West Nile Virus
SAN DIEGO--May 6, 2008--Aethlon Medical, Inc. (OTCBB:AEMD) today announced that pre-clinical studies have documented that the Aethlon Hemopurifier(R) is effective in capturing circulating West Nile Virus (WNV). The...
Omigard(TM) Phase III Pivotal Registration Study Enrollment Completed MIGENIX to Present at BioFinance and Rodman & Renshaw Conferences in May
Vancouver, BC Canada and San Diego, CA USA - May 6, 2008 - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has been notified by their partner for Omigard(TM) in North...
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
WASHINGTON, MAY 6 -- Data presented today on Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA) investigational drug candidate, iloperidone, included its 4-week, short-term Phase III trial, as well as a pooled analysis of...
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
Washington, D.C., May 6, 2008 - Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of symptoms 1 , 2 . Today, data from a new international study...
Roxane Laboratories Announces the Launch of Ropinirole Hydrochloride Tablets
COLUMBUS, Ohio, May 5 -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Ropinirole Hydrochloride Tablets, 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg by the U.S....
GORE Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study
May 05, 2008 (Flagstaff, Arizona) -- W. L. Gore & Associates (Gore) today announced that it has received approval from the US Food & Drug Administration (FDA) to proceed with the Gore REDUCE* Clinical Study. The Gore...
DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83
WINNIPEG, Manitoba - May 5, 2008 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces that it has enrolled the final patient in the...
Cordis Corporation Launches New Peripheral Angioplasty Balloon Catheters
New Orleans, La (May 05, 2008) - Cordis Corporation (NYSE:JNJ) announced today the U.S. launch of the SLEEK(TM) and SAVVY® Long PTA Balloon Dilatation Catheters, its most advanced percutaneous transluminal angioplasty...
Biocept Launches Noninvasive Prenatal Rh(D) Diagnostic at Annual ACOG Scientific meeting
(San Diego, Calif, May 5, 2008)--Biocept, an emerging leader in biotechnology, will launch I.D. Rh(D), the first in a series of noninvasive prenatal diagnostic tests that can be performed with a simple maternal blood...
Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty
LEXINGTON, Mass., May 5, 2008 -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous...
PROTEZ INITIATES PHASE II STUDY FOR ITS LEAD PRODUCT PZ-601 IN INFECTIOUS DISEASES
May 2, 2008 - Malvern, Pennsylvania - Protez Pharmaceuticals, a privately held biopharmaceutical company focused on the development of innovative antibiotics to combat drug resistant and life threatening infections,...
Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial in Neuroblastoma Patients
Cambridge, MA, May 1, 2008 - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has initiated a Phase 2a clinical trial of Azedra (Ultratrace(TM) iobenguane I-131 or Ultratrace MIBG) for the...
Biosimilar G-CSF: Cooperation on Three Continents.
Toronto, ON (May 1, 2008) -- A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals...
Merck Extends Enrollment Deadline in Program to Resolve U.S. VIOXX® Product Liability Lawsuits
WHITEHOUSE STATION, N.J., May 1, 2008 - Merck & Co., Inc. said today it has extended to June 30, 2008, the enrollment deadline for U.S. eligible claimants with cases filed or tolled by Nov. 9, 2007 wishing to be part of...
Mumbai Investigative Meeting Conducted by Criterium, Inc. Launches Clinical Study Project in India for Thrombosis Research Institute
(May 1, 2008- Saratoga Springs, NY) - A meeting at The Mumbai Hyatt Hotel hosted by Criterium Inc. and The Thrombosis Research Institute (TRI) of London, England assembled over 60 investigators from India, and marked...
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors
South San Francisco, California, May 1, 2008 - Proteolix, Inc. today announced that patient dosing has commenced in a Phase 2 clinical trial of carfilzomib (PR-171), a selective blocker of proteasome activity, in...
AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer
TUCSON, Ariz.--May 01, 2008--AmpliMed Corporation, a cancer therapeutics company, today announced that patient enrollment is underway in a Phase 2 trial of Amplimexon® (imexon for injection) in combination with...
Allon data demonstrate potential of AL-309 as a new neuropathy treatment
VANCOUVER, May 1, 2008 -- Allon Therapeutics Inc. (TSX:NPC) presented preclinical data today that demonstrate the potential of the Company's proprietary product candidate AL-309 as a treatment for peripheral neuropathy....
Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination
MARLBOROUGH, Mass.--May 1, 2008--Sepracor Inc. (Nasdaq: SEPR) today announced that it has signed a global license and development agreement with Arrow International Limited (Arrow), a European company, for a XOPENEX...
Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program
FOSTER CITY, Calif.-- May 1, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the initiation of ATHENA-1, a Phase IV, randomized, double-blind, placebo-controlled study evaluating Letairis(R) (ambrisentan 5 mg...
Phase I Clinical Trial of Photodynamic Therapy (PDT) Underway for Potential New Treatment of Oral Precancerous Lesions
WILMINGTON, Mass. (May 1, 2008) - A Phase I clinical trial, using a DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) product, has been launched by the National Cancer Institute (NCI) to study an entirely new approach for...
Nymox Announces New Positive Results at 54 Months in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
HASBROUCK HEIGHTS, NJ (April 30, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study...
SinuNase(TM) Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant Objective Evidence of Superiority of SinuNase Over Control Lavage in Severe Cases
April 30, 2008--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that continued analysis of the unblinded full data set on its pivotal Fast-Tracked Phase 3 Trial of SinuNase(TM) (topical amphotericin B...
Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
April 30, 2008 - Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced positive results of a pre-clinical study using TPM, the Company's patented drug delivery system, for the...
SPHERIX D-TAGATOSE TO BE SUPPLIED BY INALCO S.P.A.
April 30, 2008 -- BETHESDA, MD. Spherix Incorporated (NASDAQ/SPEX) announced today that it has signed letters of intent with Inalco S.p.A., an Italy-based manufacturer of bulk pharmaceutical ingredients, to supply a...
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
ASHBURN, Va., April 30, 2008 -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll...
Update on clinical study evaluating the quality of new bone generated following the use of Inion OptimaPLUS(TM)
Tampere, Finland and Guildford, UK. 30 April 2008, Inion (LSE: IIN.L), a company focused on the development and commercialisation of novel biodegradable medical implants, provides an update regarding the second clinical...
SCOLR Pharma, Inc. Announces Positive Progress for Lead Product
BELLEVUE, Wash.-April 30, 2008-SCOLR Pharma, Inc. (AMEX: DDD - News) today announced that it has received a special protocol assessment from the Food and Drug Administration (FDA) to guide the design of its Phase III...
Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
MOUNTAIN VIEW, Calif., April 30 -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in...
Lombard Medical Tech - Pivotal Trial Commences
London, UK, 30 April 2008 - Lombard Medical Technologies PLC ('Lombard Medical' or 'the Company'), the specialist medical device company, today announces the commencement of its pivotal US clinical trial for its...
MERCK SERONO ANNOUNCES INITIATION OF PHASE II CLINICAL TRIAL OF ATACICEPT IN RELAPSING MULTIPLE SCLEROSIS
Geneva, Switzerland, April 30, 2008 - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced the initiation of a Phase II clinical trial to evaluate...
Encouraging first-quarter 2008 results - Further positive Phase III results for eplivanserin
April 30, 2008 - Sanofi-aventis generated first-quarter net sales of EUR6,937 million, a rise of 0.8%. Exchange rate movements had an unfavorable effect of 4.5 points, mainly due to the U.S. dollar. Changes in Group...
Merck Announces Initiation of Phase II Clinical Trial of Atacicept in Relapsing Multiple Sclerosis
Darmstadt, April 30, 2008 - Merck KGaA announced today that its Merck Serono division and ZymoGenetics, Inc. (NASDAQ: ZGEN) are initiating a Phase II clinical trial to evaluate the safety and efficacy of atacicept in...
Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis
SEATTLE, Apr 30, 2008 -- ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced that its development partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has initiated a Phase 2 clinical trial to evaluate the...
ZymoGenetics Presents Positive Results from RECOTHROM(TM) Thrombin, topical (Recombinant) Spray Study in Burn Patients
SEATTLE--April 30, 2008--ZymoGenetics, Inc. (NASDAQ:ZGEN), today presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM(TM) Thrombin, topical (Recombinant) administered by...
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
IRVINE, Calif., April 30, 2008 -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive results from the preliminary analysis of its second and final Bepreve(TM) (bepotastine ophthalmic solution) Phase III...
Chemokine Therapeutics Announces Liver Cancer Data Presented at the AACR Meeting on its Lead Compound, CTCE-9908
Vancouver, BC (April 30, 2008) - Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood...
SkyePharma Announces Flutiform(TM) Phase III Efficacy Study Meets Primary Endpoints
LONDON, UK, 30 April, 2008 - SkyePharma PLC (LSE: SKP) today announces that its Phase III efficacy study evaluating Flutiform(TM) for the treatment of asthma in adolescent and adult patients, met its primary endpoints....
Cytokinetics Announces the Initiation of Second Phase IIa Clinical Trial of CK-1827452
South San Francisco, CA - April 29, 2008--Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the initiation of its second Phase IIa clinical trial evaluating CK-1827452, a novel cardiac myosin activator being...
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
TUSTIN, Calif., April 29, 2008 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection...
Expanded Formulation and Analytical Development Laboratories open
On 29th April 2008, just 36 months after moving into new premises in Livingston, Encap Drug Delivery, in partnership with Thermal Transfer, has completed the first phase of its next extension by opening a major new 200...
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of RITUXAN in Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. -- April 29, 2008 -- Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that a Phase II/III study of Rituxan® (rituximab) for systemic lupus...
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
SOUTH SAN FRANCISCO, Calif. - April 29, 2008 - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced today that its lead product candidate, R788, has successfully treated lupus prone mice and significantly improved their...
Eurand Announces Launch of OTC Unisom® SleepMelts by Chattem
Milan and Dayton - April 29, 2008 - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its...
Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
MOUNTAIN VIEW, Calif., April 29 -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced positive results from a Phase 1 clinical trial of AZ-007 (Staccato(R) zaleplon). AZ-007 is an inhalation product candidate...
CeraShield(TM) Coated Urinary Catheters Provide Superior Protection Against Bacterial Colonization Compared to Leading Brands in Preclinical Testing
DENVER, Apr 29, 2008 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, today presented data on its urinary...
Orexo reports positive results from phase I study for OX19
April 29, 2008 -- Orexo Pharmaceuticals -- Many elderly people suffer from nocturia and in particular amongst women, incontinence is a common problem. Treatment with the peptide desmopressin is currently the most...
Inhibitex Initiates Phase I Trial of FV-100 for the Treatment of Shingles
ATLANTA-- April 29, 2008--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, today announced that its Investigational New Drug...
Nuvelo Announces Positive Proof-of-Concept Data With Anticoagulant NU172
SAN CARLOS, Calif., April 29, 2008 -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 proof-of-concept trial (n=30) of NU172, demonstrating that the thrombin-inhibitor achieved rapid onset...
Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
EVANSTON, Ill., April 29, 2008 -- Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that Steven A. Gould, M.D., Chairman and Chief Executive Officer, presented a talk on the clinical development of...
Acusphere Submits New Drug Application for FDA Approval of Imagify(TM)
WATERTOWN, Mass., Apr 28, 2008-- Acusphere Inc. (NASDAQ: ACUS) announced today the submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for approval to market its lead product...
Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
BOTHELL WA, April 28, 2008 -- Mirabilis Medica, a privately-held medical device company, today announced completion of its first human trial, which served as a preliminary demonstration of clinical feasibility of its...
Millions of Patients May Find Hope in a New Implantable Device Designed to Lower High Blood Pressure in Drug Resistant Hypertension Patients
Minneapolis --April 28, 2008--May is Hypertension Awareness Month, and a new device in high blood pressure clinical trials is showing promise for treating U.S. hypertension (high blood pressure) patients whose condition...
KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003
PALO ALTO, California, April 28, 2008 - KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced that the company has completed dosing subjects in a U.S. Phase 1 clinical trial of its...
INTERCURE SECURES NATIONWIDE DISTRIBUTION AGREEMENT WITH LLOYDS PHARMACY GROUP
New York, NY and London, UK -- April 28, 2008 -- InterCure Ltd., a medical device company publicly traded on the Tel Aviv Stock Exchange (TASE: INCR), today announced that its RESPeRATE® hypertension treatment device,...
Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration
Leverkusen, Germany and Tarrytown, NY, April 28, 2008 - Bayer HealthCare AG and development partner Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that VEGF Trap-Eye dosed on a PRN (as-needed) dosing...
ROXRO Pharma Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
MENLO PARK, CA (April 28, 2008) - ROXRO PHARMA, Inc. today announced positive top-line data from a clinical study of the company's novel investigational intranasal pain reliever in the treatment of migraine and related...
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
TARRYTOWN, N.Y. & LEVERKUSEN, Germany--April 28, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that VEGF Trap-Eye dosed on a PRN (as-needed) dosing schedule maintained the...
Metabasis Therapeutics Announces Positive Results in the Phase 2a Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes
SAN DIEGO -- April 28, 2008--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that MB07803 met its primary efficacy endpoint with results demonstrating a statistically and clinically significant reduction in...
Fluidigm Launches New BioMark(TM) IFC Controller MX
Monday, April 28, 2008, South San Francisco, CA -Fluidigm Corp. is announcing the availability of its new BioMark(TM) IFC Controller MX, part of the company's complete system for high-throughput genetic analysis.
Encorium Group, Inc. expands its European operations with the opening of an office in the Cologne area, Germany, Encorium Germany GmbH
WAYNE, PA, April 28, 2008 - Encorium Group, Inc. (Nasdaq: ENCO) a global clinical research organization (CRO) specializing in the design and management of complex clinical trials and Patient Registries for the...
MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 Program
April 28, 2008 -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the completion of a first dosing regimen in a phase 1 clinical study on healthy volunteers of the HuCAL-derived antibody MOR103...
Lupin Launches SUPRAX ®400 mg Tablets in the US
April 28, 2008, Mumbai, India -- Lupin Ltd. (Lupin), announced today that its subsidiary, Lupin Pharmaceuticals Inc (LPI), has launched Suprax® 400 mg Tablets (Cefixime USP) in the US.
LGC Forensics launches DNA SenCE - A unique method for analysing trace amounts of DNA
April 28, 2008 -- LGC Forensics, the UK´s largest independent provider of forensic services, is pleased to announce that its latest innovation, DNA SenCE, is now in operational use with several police forces.
Gene Therapy Improves Vision in Small Clinical Trial
April 27, 2008 -- Based on those findings, physicians will proceed with additional clinical trials to investigate the treatment for Leber congenital amaurosis (LCA), an inherited disease that causes severe visual...
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
PRINCETON, N.J. and MILAN, Italy, April 25, 2008 -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys...
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25, 2008 -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced today that the FDA has provided guidance regarding approval requirements for...
AkzoNobel Launches New Brand Strategy
April 25, 2008 -AkzoNobel has launched its new corporate brand. Symbolizing the company's fundamental transformation and determination to lead change, it embodies AkzoNobel's clear ambitions for the future and a...
NeuroSearch initiates pivotal Phase III programme with ACR16 for the treatment of Huntington's disease
April 25, 2008 -- NeuroSearch has enrolled and dosed the first patients in a European Phase III study, thereby launching the pivotal clinical programme with ACR16 for the treatment of Huntington's disease. The Phase III...
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
PRINCETON, N.J. and MILAN, Italy, April 24, 2008 -- Pharmasset, Inc. (Nasdaq: VRUS) will enroll two additional cohorts in the on- going Phase 1 study protocol to evaluate 4 weeks of combination therapy with R7128....
Clinical Update - PSD508 for Dysmenorrhoea
April 24, 2008 -- Plethora Solutions Holdings plc ("Plethora", AIM: PLE), the specialist developer of products for the treatment and management of urological disorders, is pleased to announce the completion of patient...
Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
SAN DIEGO, April 24, 2008 -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has initiated a Phase II study of its small-molecule thrombopoietin (TPO) mimetic, LGD-4665. The 24 patient,...
Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment
MILAN, Italy, Apr 24, 2008 -- In a late-breaker poster presentation at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today will present data from an interim analysis...
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us